Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies

NCT07503353 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT07503353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07503353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies
Lead sponsor
Sheba Medical Center
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
January 31, 2030
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphobkastic leukemia, b cell malignancies, non-hodgekin lymphoma (nhl-both follicular & diffuse large cell)